Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...

Thank you for joining us for Eli Lilly and ... We acquired Morphic Therapeutics and announced a collaboration with OpenAI to invent novel antimicrobials. We opened the Lilly Seaport Innovation ...

Regulatory approvals for Kisunla, Ebglyss, and Zepbound in 2024 were noted as critical milestones, alongside the acquisition of Morphic Therapeutics ... differentiation. Eli Lilly ended 2024 ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.